

EDP: STGs & EDL Audits

Compiled and Presented by Mariam Cassimjee (Clinical Quality Improvement)



KwaZulu-Natal Department of Health

Outline of Presentation Definition of Rational drug Use (RDU) Purpose of compliance tests Description Results & Analyses Reports & Recommendations Follow-up after an audit Continual Monitoring, training and planning

Rational Drug Use

- Is defined as the practice of using drugs:
- Appropriately for a clinical condition,
- In the correct
 - Formulation
 - Doses that meet the patient's individual requirements
 - Frequency
- For an adequate period of time
- And at the lowest cost.

NDP-EDP: EDL Drug selection

- Must meet the health needs of the majority.
- Sufficient proven scientific data for inclusion.
- Substantial safety and risk / benefit ratio
- As a rule, single ingredient
- Convenience of dosage regimen
- When all equivalent, then only are costs considered.
- All drugs must be used within standard treatment guidelines.

Efficacy: Safety: Dosing Convenience: Costs

Purpose of an Audit

- For the facility to note their strengths & weaknesses i.t.o following the EDP
- To do a turnaround of problem working in partnerships with all departments → for positive growth & interventions using a monitoring, training and planning approach.
- To promote self-auditing using the tools employed in the auditing exercise or alternate measures
- To measure progress over time
- To re-evaluate after reasonable intervals to promote further change or to detect new problems

Tools Used in KZN

"Adherence of KZN Facilities to the Essential Drug Programme"

> Adapted by Mariam Cassimjee from: -WHO's "How to investigate drug use in health facilities" Piloted in the Ugu District by K Ramasir & M Cassimjee On the 19 & 20 August 2003 & 03 & 04 March 2004

Other Tools Used

For correct prescribing of top budget items: -

1. ABC analysis \Rightarrow A = top 20% consuming ± 75% of budget p.a.

B = 15% of budget, &

C = 5% of budget.

- Drug Order Reviews → follow on from ABC analysis → determines orders for specific drug/s from PMSC for specific facilities
- 3. Prescriber indicator analysis for STG compliance \rightarrow DUR

(1) and (2) are used provincially \rightarrow to determine whether the facility needs to be audited for STG compliance i.r.o. the drug being investigated \rightarrow Drug Utilisation Review (DUR)

For a facility's self auditing: ABC analysis can be sourced & DURs conducted internally.

Description of "Adherence to EDP-STG" Tool

- 1. Questionnaire : assesses knowledge, attitude, application of the EDP & a STG for a prevalent condition in the community (e.g. hypertension) to enable interventions in practice
- 2. Assessments against WHO prescriber indicators: of retrospectively randomised prescriptions within a time frame to determine the degree to which the health facility conforms to the EDP: STGs & EDL.
- 3. Investigation of an Identified Drug: Using WHO indictors for STG compliance to determine RDU.
- 4. Assessment of the availability of key EDL items: Uses a sample of 20 EDL drugs for spot checks.

Form: Prescribing Indicators for STGs & EDL

No	Date	Age in Yrs	Drugs	No of Drugs Prescribed Generic ally	Anti- Biotic (0/1)*	Injec- tion (0/1)*	As per STG (0/1)*	Diagnosis
1	3.6.06	45	Hydrochlorothiazide 12.5mg; Atenolol 50mg; Brufen 200mg; Ventolin Inhaler (4)	2	0	0	0	HPT; Chronic Asthma
2	7.8.06	58	Hydrochlorothiazide 12.5mg; Enalapril 10mg b.d.; Salbutamol Inhaler prn; Budesonide Inhaler (4)	4	0	0	1	HPT; Asthma
3	3.8.06	59	Actraphane 40u mane. 20 u nocte; Erthromycin 500mg qid (2)	2	1	1	0	Diabetes & Flu
4	5.3.06	1⁄4	Sorbitol 70%; Fosenema; Dulcolax suppository (3)	1	0	0	0	??
30 = (A)								
Total No of Drugs		f	(B)	(D)	(F)	(H)) (၂)	
Average			(C) =B/A					
Per	centag	e		(E)	(G)	(I)	(L)	

Problem Drug Investigation e.g. Amlodipine 5 mg:

Location: Xixo Hospital

Investigator: <u>M Cassimjee</u> Date: <u>30.09.06</u>

No #	Date	Age in Yrs	Dept/ Clinic	Drug Name/s as Prescribed	Prescribed Generically (0/1)*	As per STG (0/1)*	Diagnosis
1	3.6.06	36	OPD	Norvasc 5mg	0	0	HPT
	8.9.06	45	MOPD	Amlodpine 5mg	1	1	ISH
30							
Tota		l					
Perc	entage						

Results & Analyses

Calculations

Interpretations against STGs

Analysis for reports

Results of Pilot Sites: Baseline (8/2003) & Post (3/2004) Study

Indicators Used	PHC Clinic		District Hosp		Regional Hosp	
	Base	Post	Base	Post	Base	Post
Understanding & promoting core concepts of the EDP- Percentage score: (Pharmacy or facility Manager)	90	85	40	70	25	45
Average No. of drugs per encounter	2.3	1.7	3	3.8	3.6	3.2
Percentage drugs prescribed generically	55	80	35	23	0	16
Percentage encounters with an antibiotic	55	43	37	9	6.7	17
Percentage injections prescribed per encounters of sample	6.7	27	30	23	6.7	23
Percentage drugs prescribed according to the EDP - STGs	15	80	14	50	6.4	60
Problem areas: %age for the correct prescribing of antibiotic/statin/NSAID injection (A=Amoxycillin) (I = Diclophenac sod) (S= Atorvastatin /Simvastatin)	50 (A)	60 (A)	0 (1)	80 (I)	3.9 (S)	83 (S)
Percentaage for the availability of EML Items	95	100	100	100	100	100

Marked Improvement after intervention(DURs, Compliance Tests & Recommendations)

Questionnaire Result – Pharmacy Manager

Indicator	Result	Comments
Understanding & promoting core concepts of the EMP- Percentage score: (Pharmacy or facility Manager)	97.5	Well done! Understanding the concepts makes application easier and promotable within the department and the facility.

Average No of Items Example 1

Indicator	Result	Comments
Average No. of drugs per encounter	4.8	Were read against the STGs as indicator for correct usage. The norm for a district facility is 3. A value of $4.8 \rightarrow ??$ RDU.

Av No. of Drugs Per Encounter

Hosp 1	Hosp 2	Comments
		Norm \rightarrow 3.0 for hospitals
4.3	5.8	Some consideration is made for prescriptions with multiple chronic diseases.
		But there is strong evidence of polypharmacy!

T	PATIENT'S NAME:	I.D. NUMBER:			
DATE	MEDICAL DATA	PRESCRIPTION Prescription must include Doctor's full signature and qualifi (In terms of the National Drug Policy, prescriptions should be written u (generic) drug name).	cations. sing the approved	QTY ISSUED	FOR PHARMA USE
LUAU	OID File lost	Has 3 diff. P/land	OR EQUIV.		
A	Astlinian _	(Dermotology Ha- all	Sayle EQUIV.		1
0830	Octopacin_ 1	() HUID- OPD	OR EQUIV.		
TRI	Ecgana Bf 120/50		OR EQUIV.		
1.94	120	Kx Arthurd B	OR EQUIV.	C	
	Chul 120	. Dyland (B)	OR EQUIV.	C	
	Churt the	Nucleu Str 150	OR EQUIV.	56	
2 Items	Comments:	Cometade 200 y bd	OR EQUIV.	56	2
		CTM 47. W.t	OR EQUIV	TA	
	ard → problems for Pt, Dr & fac ffice problem	2	OR EQUIV.	m	28
		Bereter 125 Unite	OR EQUIV.		0
	ach used→ no peak flow to con of all asthma meds or checks or		I OR FOLIN		51
	t technique for inhalants		OR EQUIV.	7	<1 C1
		K. Adventer Out	OR EQUIV.	Ŧ	
	view → rewriting of Rx → propaging ypharmacy + workload!		OR EQUIV,	30 \$	-
		Anne krysty the I car und	OR EQUIV.	284	
	^c Theophyllin → LABA usually be hyllin – ?? QOC & infringement		OR EQUIV.		
policy.			OR EQUIV.	17	
	ity vs need of all other meds?		OR EQUIV.	1871	6
	ing the model of all other medal		OR EQUIV.	100	

Polypharmacy: Safety Issues w.r.t. Drug Interactions

No	Rx	Comment
1	Asthavent	Polypharmacy demands monitoring as-
2	Inflammide	• Cimetidine \uparrow theophylline conc \rightarrow \uparrow 70% SEs \rightarrow possible cardiac arrythymias, tachycardia,
3	Nuelin SA i b.d.	convulsions. (Mech \rightarrow inhibition of CYP450
4	Cimetidine 200mg b. d. (Sh be 400mg nocte for 2 wks only→ for investigation thereafter)	 enzymes resp for theophylline metabolism.) Cimetidine ↑ conc of TCAs to toxic levels in some pts. (Mech → inhibition of CYP450 metabolism of TCAs. MANAGEMENT: Close monitoring for clinical
5	CTM 4mg b.d.	response & tolerance recommended whenever cimetidine is +ed or discontinued from a TCA regimen.
6	Premarin 0.625mg	•Co-administration with inhibitors of CYP450 3A4 \rightarrow
7	Berotec 1.25 mcg (10)	↑ plasma conc & systemic effects of budesonide (metabolized by the isoenzyme). Acc to budesonide
8	Ca Hexal (dose details - not clear)	labelling, potent 3A4 inhibitors $\rightarrow \uparrow$ plasma levels of budesonide severalfold e.g. 8 fold \uparrow systemic
9	Steroid V b.d.	exposure (AUC) of oral budesonide observed when
10	Advantan ointment	co-administed with ketoconazole → leading to Cushing's syndrome with impaired adrenal function
11	Alendronnate 10mg daily	MANAGEMENT: The possibility of \uparrow systemic pharmacologic effects of budesonide sh be
12	Amitriptyline 10 b.d.	considered during concomitant therapy with CYP450 3A4 inhibitors,

More Harm than Good!

No	Rx	Comment
1	Indocid supps i nocte	
2	ASA ½ daily	
3	Tenormin 100mg o.d.	Should never be prescribed for an asthmatic – induces an episode. A beta agonist and a beta blocker on the same prescription!
4	Renitec 10 mg b.d.	
5	Norvasc 10 mg daily	
6	Isordil 10 mg t.d.s.	
7	Daonil 5 mg b.d.	
8	Asthavent	

Prevention vs Relief

No	Rx	Comment
1	HCT ½ daily	No inhaled steroid in an
2	Asthavent	asthmatic!
3	Theodur 200mg b d	Relievers are the mainstay of this prescription in contrast to the STGs.
4	Buscopan 20mg t d s	The preventer (inhaled steroid) would eliminate
5	Paracod ii prn	the need for the theophyllin (Nuelin) and would afford quality of care.
6	Tinaderm Ointment	

Theophylline: Prescriber Level 3

■ PL 3 → restricted to specialists & to respiratory clinics.

Rational prescribing not determined on price but on optimising the care of the patient.

Omission of the inhaled steroid in confirmed asthmatic -> viewed as compromised care!

Drugs Prescribed According to EDP - STGs

Indicator - STG	Result	Comments
Percentage of drugs prescribed according to the EDP - STGs	9.8	Only 14/143 drugs prescribed in the sampling were acc to the STGs. Concerns are raised w.r.t. this aspect and needs urgent attention.

Generic Prescribing

Indicator	Result	Comments
Percentage of drugs prescribed generically	6.3	In promoting compliance, pts needs to know their medicines. Prescribers & pharmacists need to write & talk "generics" esp when counseling. In state facilities, brand names change with the tenders & brand promotions have to be avoided.

Generic Prescribing

- 1. In state facilities, brands change with the tenders.
- 2. Can patients know their chronic meds & names when Drs talk brand names and pharmacists dispense and counsel on generics? (Compliance?)
- 3. Internationally → there are significantly fewer generic names than brand names
- 4. Generic names are international: Brand names may vary between countries
- 5. Exclusive use of generic names for all prescribers: simplifies learning, teaching and reduces confusion
- 6. Generic names indicate chemical class → drug's pharmacology and classification
- Generic nomenclature used routinely in medical & scientific publications → info more accessible if generic names are consistently used.

Antibiotic Use / Misuse

Indicator	Result	Comments
Percentage of encounters with an antibiotic	23	Good! 5 out of 7 Rxs with an antibiotic were acc to STGs = <u>71% correct!</u> One of the other 2 Rxs used cotrimox for a UTI with no data on sensitivities for justification.

Percentage of Encounter With an Antibiotic

Hosp 1	Hosp 2	Comments
33%	6%	Hosp 1: Most were rationally prescribed except use of the more expensive erythromycin in place of amoxycillin! Hosp 2: Overall small value but for erythromycin usage

Injection Use

Hosp 1	Hosp 2	Comments
30%	8.7%	Hosp 1: Most were non-compliant – use of diclophenac inj (separate audit conducted) Hosp2: Most were judiciously prescribed as insulin for DM except for diclophenac 75mg injection (separate audit)

Percentage: <u>Correct</u> Use of Diclophenac Sod 75mg Inj.

Hosp 1	Hosp 2	Comments
13.3	3	Hosp 1: translates to 86.7% injudicious use Hosp 2: translates to 97% injudicious use

Used for the following: -

"HPT – FFD"; "body pain with flu", "tender thigh", "in pain but comfortable", "mild swelling", "PVD & UTI", "arthalgia with ibuprofen" & "Asthma with HPT"→ all not severe to warrant diclophenac injection.

STGs are for safety of $Pt \rightarrow Inj$ reserved for IP, Orthopaedics & Casualty with restrictions for conditions where it would not be warranted.


Percentage Drugs Prescribed According to the EDP - STGs

Hosp 1	Hosp 2	Comments
87 %	54%	Hosp 1: Very Good! Hosp 2: Translates to a non- compliance of 46%

Prices of Anti-HPT Agents: PMSC's catalogue of Nov 2006

Tablet Preparations for HPT	Price	Price per Tablet	Rating per Price
Amlodipine besylate tab eq to amlodipine base 5mg; 30's	R 20.10	67 c	6
Atenolol tablets patient ready pack; 100mg; 28's	R 6.75	24c	5
Atenolol tablets 50mg; 28's	R 3.56	13c	4
Enalapril maleate tablets patient ready pack; 5mg; 28's	R 2.31	80	2
Enalapril maleate tablets 10mg; 28's	R 2.56	9c	3
Hydrochlorothiazide tablets patient ready pack; 25mg; 14's	78c	6c	1

Should the usage not follow the STGs for cost effectiveness?



Ca++ Channel Blocker: Compelling Indication for Specific Class – SA HPT Society 2004 & EDP

- Diabetes mellitus with proteinuria: ACE inhibitor
- Evidence of CHD/Stroke/PVD/OR diabetes <u>OR</u> 1 major risk factor: ACE inhibitors
- Heart failure diuretics and ACE inhibitors
- Isolated systolic hypertension thiazide/long acting calcium channel blocker
- MI beta-blockers/ACE inhibitors
- Pregnancy methyldopa

Problem Drugs: Ca⁺⁺ Channel Blockers % age for <u>Correct</u> Prescribing

Hosp 1	Hosp 2	Comments
22%	30%	Expensive prescribing! Hosp 1: 88% non- compliance Hosp 2: 70% non-compliance!

Calcium Channel Blocker Usage

Hosp 1

Review Period	Drug	Units Used	Unit Cost	Costs over 9 Mths	Comment
11.11.04 to 19.08.05	Nifedipine 30mg XL	23 220	R26.47	R 614 633	(Data for 9 months)
01.10.05 to 31.12.05	Amlodipine 5mg	12 900	R20.10 N.B. ↓ in unit costs	R259 290	R 1 037 160 Projected annual expenditure

Hosp 2					
11.11.04 to 19.08.05	Nifedipine 30mg XL	72,720	R26.47	R1,924,898.40	(Data for 9 months) Highest use in KZN!
01.10.05 to 31.12.05	Amlodipine 5mg	18,640	R20.10 N.B. ↓ in unit costs	R374,664.00	R1,498,656.00 Projected annual usage Highest user in province!

Problem Drug: Nifedipine 30mg XL (2004)

Indicator	Result	Comments
Problem areas: Percentage for the <u>correct</u> prescribing of Nifedipine 30 mg XL	30	Translates to 70% incorrect usage! Considering Nifedipine is the most expensive of the HPT agentsts at 95c per tab → HCT - 7c, atenolol 50mg – 12c, atenolol 100mg 22c, enalapril 5mg – 11c & enalapril 10mg – 13c, should the usage not be judicious?

Facility's annual usage = R 521,009.01 (20/10/2003 to (19/10/2004).

Cost Implications of Incorrect Usage of Ca++ Channel Blockers

With use of ACE-I (at highest dose of 10mg b.d.) acc to STGs \rightarrow big cost savings!

Hosp 1: 88% non-compliance

0.88 * 12 900/3*12*= 45408 units annualy → R912 700.8

Possible savings using ACE-I = R680 211.84 (= R912 700.8 - R232 488.96)

Hosp 2: 70% non-compliance

0.7*180640/3*12= 52 192 units annually → R1 049 059.20

Possible savings using ACE-I = R781 836.16 (R1 049 059.20 - R232 488.96)

Problem Drug 2004: Captopril 25mg

Indicators Used	Score		Comn	nents	
%age for <u>correct</u> prescribing of Captopril 25mg		Captopril →reserved for Paeds & emergency HPT on the STGs. Should these prescription be dispensed? Data below is worth considering for better patient compliance and BP control. References: Opie L H, Angiotensin Converting Enzyme Inhibitors; Shionoiri et al 1986			
			t _{1/2} - hrs	t _{max -} hrs	Dosing frequency
	Captopril	1.2	1.5	t.d.s.	
		Enalapril	6	6	b.d.

Availability of EDL Items

Indicator	Score	Comments
Percentage for the availability of EML I tems	85	 A 100% is the expected norm. Concerns → 3 items: - 1. TB continuation phase packs for <u>adults & children</u> were not stocked. Management of TB in-pts + TTOs? 2. O/s Ferrous sulph: a supply problem; been arriving intermittently from PMSC since Aug 2004.

Problem Prescription: Quality of Care

27 October 2004

- Polypharmacy 15 items (Rx <u>not included</u> in the retrospective sample)
- <u>Transcribed by nurse and signed by MO!</u>
- Diagnosis on prescription HPT, diabetes, arthritis and coughing!

HCT 25mg		Asthavent refill			
	2 diuretics?	ABS Nebs Solution			
Lasix 40mg		Inflammide 200µg bd			
		Neulin SA 250mg bd			
Daonil ii – i		Premarin 0.625mg daily			
Glucophage 1G tds		Benylin 10ml tds – Neccessity?			
Reserpine 0,2	5mg (No longer on STGs)	CTM 4mg tds	* 2 Aha		
Isordil 10mg t	ds	Amoxil 500mg tds			

Questions: -

Disprin ½ D

- Review for correct inhaler usage, technique & need for cough mixture?
- Dosage & frequency adjustments → Nebs, Salbutamol & Budesonide?
- K⁺ levels → Frusemide + HCT + Salbutamol
- Compromise of quality of care → drug related problems?
- Scope of practice of nurse practitioner → MO signing a transcription with pharmacist dispensing the Rx!

Problem Rx – Referral

Transcribed from poorly compiled referral without necessary concise details.

27 Oct 2004 – 12 items

- 1. Diamicron 80mg tds
- 2. Glucophage 500mg tds
- 3. Ismo 20mg bd
- 4. TNT 1 prn
- 5. Aspirin ¹/₂ daily
- 6. Lasix 40mg bd

- 7. Slow K 1 bd
- **8.** Enalapril 5mg tds
- 9. Zocor 10mg nocte
- 10. Tenormin 50mg bd
- 11. Dolorol F 1-2 prn
- 12. Fybogel 1 nocte

Comments & Recommendation

- Areas of positiveness (knowledge of pharmacy manager & antibiotic usage!)
- Need to workshop STGs for improvement
- Self audits (facility & personal practices) → will spearhead success
- Liaison with all prescribers for change.
- Written evidence of the pharmacists' interventions is a legal requirement → need retrievable documentation for correlations & communication between the <u>varying</u> <u>prescribers and pharmacists</u> → holistic practices and care.

Other Areas of Concern

- Optimisation for Pt & prescriber: All Rxs → written & signed by prescriber → not within the scope of practice of nurse practitioner to write up script for doctor.
- Transcriptions: Need addressing for safety of pt. → correctness, legal cover of prescriber.
- Referrals: How should these be handled? Mere transcriptions without concise details
 to enable checks and afford legal cover?

Follow-up after an Audit

Baseline can be followed up by post tests after reasonable period to allow for improvements (± 6 months later)

■ Facility: self audits enabling → same tools

Advocate monitoring, training, and planning for continued success \rightarrow (MTP) \rightarrow in-house CE formats

Continual "Monitoring, Training & Planning"

Can be self-initiated, self-planned, self-executed, and selfevaluated by the hospital team



Recommendations for RDU

- **1.** Rank or rate problems to prioritise corrections.
- 2. Which needs attention upfront or can problems be rectified concurrently?
 - Polypharmacy
 - Prescribing according to the EDP STGs
 - Generic prescribing
 - Use of long acting Ca⁺⁺ channel blockers (Amlodipine 5mg) - HPT STGs
 - Antibiotic use STG or injection use (diclophenac sod 75mg)

Criterion	Poly- pharmacy	STG Adherence	Generic Prescribing	Antibiotic Use
Scale of Problem				
Seriousness of effects				
Costs				
Appropriate ness				
Total Rate or Rank				

To Succeed: Need

 An accountable management team to perform audits and feedback (to include antimicrobial resistance data – infection control)

 Motivated management and staff with commitment

Acknowledgements

K Ramasir (District Pharmacy Manager): Piloting compliance tools in the UGU District, KZN.

WHO Publication: "How to investigate drug use in health facilities"

Innovative Strategies to Improve Prescribing: The Pleasant Journey from Field-test to Institutional Program"; Dr Sri Suryawati; ICIUM 2004